ADXS Advaxis Inc.

0  0%
Previous Close 3.31
Open 3.3
Price To Book 0.71
Market Cap 26503117
Shares 8,006,984
Volume 64,769
Short Ratio
Av. Daily Volume 549,897

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Enrollment to be terminated - noted November 2, 2018.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Phase 1 monotherapy, overall survival was 8.5 months, combo with Keytruda 23 months.
ADXS-PSA and Keytruda - KEYNOTE-046
Castrate-resistant prostate cancer
Phase 3 partial clinical hold announced January 23, 2019. No new enrolments permitted until hold released.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
HER2-driven malignancies - cancer
Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
Axalimogene filolisbac
Anal cancer (FAWCETT)
Phase 1 safety and immunogenicity data presented at AACR March 2019
Non-small cell lung cancer (NSCLC)
Phase 1/2 safety, tolerability and immune correlative data due by the end of June 2019.
Non-small cell lung cancer (NSCLC)

Latest News

  1. Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know
  2. QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
  3. Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
  4. Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?
  5. Why Range Resources, Advaxis, and StoneCo Slumped Today
  6. The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings
  7. Advaxis' stock plummets after public offering prices at deep discount
  8. Advaxis Announces Pricing of Its Public Offering of Common Stock
  9. Advaxis, Inc. Announces Proposed Public Offering of Common Stock
  10. Advaxis Up on Positive Early-Stage Immunotherapy Study Data
  11. Why Wynn Resorts, Advaxis, and Roku Jumped Today
  12. Why Advaxis Stock Skyrocketed 13.8% Today
  13. Advaxis Shares Surge After Positive Clinical Trial Updates
  14. Reverse Split and New Clinical Data, What's Next for Advaxis?
  15. Biotech News: Why Advaxis Stock Is Soaring Today
  16. ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer
  17. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
  18. Preliminary Data from Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity and Clinical Activity
  19. Advaxis Announces Reverse Stock Split
  20. Top Ranked Momentum Stocks to Buy for March 28th